Squarepoint Ops LLC Boosts Position in Becton, Dickinson and Company $BDX

Posted by Brian Himes on Sep 9th, 2026

Squarepoint Ops LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 2,758.1% in the 2nd quarter, Holdings Channel.com reports. The fund owned 253,485 shares of the medical instruments supplier’s stock after purchasing an additional 244,616 shares during the period. Squarepoint Ops LLC’s holdings in Becton, Dickinson and Company were worth $38,360,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Larson Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares in the last quarter. Brown Lisle Cummings Inc. boosted its stake in Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after buying an additional 54 shares during the period. Atlantic Union Bankshares Corp grew its position in Becton, Dickinson and Company by 0.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after buying an additional 57 shares in the last quarter. Elevation Point Wealth Partners LLC increased its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after acquiring an additional 62 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 2.9%

NYSE:BDX opened at $179.35 on Wednesday. The firm has a market capitalization of $49.42 billion, a P/E ratio of 54.02, a P/E/G ratio of 13.02 and a beta of 0.21. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a fifty day moving average of $171.21 and a 200 day moving average of $160.61. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. Bank of America increased their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Wells Fargo & Company raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Finally, Royal Bank Of Canada raised their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $187.67.

View Our Latest Research Report on Becton, Dickinson and Company

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,005 shares of company stock valued at $1,423,580 over the last quarter. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells medical devices, diagnostic products and laboratory equipment. Its offerings support healthcare providers, researchers, pharmaceutical manufacturers and patients across areas such as medication delivery, infection prevention, specimen collection, surgery and disease diagnosis.

BD’s products include needles, syringes, catheters, infusion and medication-management systems, injection devices, blood-collection products, diagnostic testing platforms, laboratory automation equipment and flow cytometry systems.